GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Toleranzia AB (OSTO:TOL) » Definitions » Institutional Ownership

Toleranzia AB (OSTO:TOL) Institutional Ownership : 0.01% (As of May. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Toleranzia AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Toleranzia AB's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Toleranzia AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Toleranzia AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Toleranzia AB Institutional Ownership Historical Data

The historical data trend for Toleranzia AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Toleranzia AB Institutional Ownership Chart

Toleranzia AB Historical Data

The historical data trend for Toleranzia AB can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Toleranzia AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Toleranzia AB (OSTO:TOL) Business Description

Traded in Other Exchanges
N/A
Address
Erik Dahlbergsgatan 11A, Gothenburg, SWE, SE-411 26
Toleranzia AB is a pharmaceutical company based in Sweden. The company's drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an orphan disease.